Usefulness of monitoring mycophenolic acid exposure in systemic sclerosis-related interstitial lung disease: a retrospective cohort study.
Connective tissue diseases
Interstitial lung disease
Mycophenolic acid
Pharmacology
Scleroderma
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
received:
15
08
2024
accepted:
22
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
Systemic sclerosis-related interstitial lung disease (SSc-ILD) represents a significant cause of morbidity and mortality in Systemic Sclerosis (SSc). Mycophenolate mofetil (MMF) is currently the first line treatment for SSc-ILD. There is no recommendation on the dosage of mycophenolic acid (MPA) blood concentrations, so we aimed to study the correlation between MPA exposure and respiratory outcomes in this population. We conducted a retrospective cohort study of SSc-ILD patients treated with MMF in our center. According to our policy, a complete patient evaluation was performed approximately one year after MMF initiation, during which the mycophenolic acid (MPA) residual rate (RR) was measured. We analyzed the association between RR and changes in forced vital capacity (FVC) and diffusion capacity for carbon monoxide (DLCO) over time. Forty-three SSc-ILD patients were included. Patients with higher RR levels (≥ 1.5 mg/L) had a significantly better FVC evolution with a higher proportion of stabilization and lower proportion of FVC decrease (p = 0.024). RR above 1.5 mg/L was a predictive factor of reduced FVC decline compared with lower RR levels adjusting for MMF dose and duration of MMF exposure (p = 0.008). There was no difference regarding DLCO outcome. Our study suggests that optimal MPA exposure, as indicated by RR levels, may better protect against FVC decline in SSc-ILD patients treated with MMF. Routine monitoring of MPA exposure could be beneficial in optimizing treatment outcomes. Prospective, multicenter studies are needed to further explore the relationship between MPA exposure and clinical outcomes in SSc-ILD.
Sections du résumé
BACKGROUND
BACKGROUND
Systemic sclerosis-related interstitial lung disease (SSc-ILD) represents a significant cause of morbidity and mortality in Systemic Sclerosis (SSc). Mycophenolate mofetil (MMF) is currently the first line treatment for SSc-ILD. There is no recommendation on the dosage of mycophenolic acid (MPA) blood concentrations, so we aimed to study the correlation between MPA exposure and respiratory outcomes in this population.
METHODS
METHODS
We conducted a retrospective cohort study of SSc-ILD patients treated with MMF in our center. According to our policy, a complete patient evaluation was performed approximately one year after MMF initiation, during which the mycophenolic acid (MPA) residual rate (RR) was measured. We analyzed the association between RR and changes in forced vital capacity (FVC) and diffusion capacity for carbon monoxide (DLCO) over time.
RESULTS
RESULTS
Forty-three SSc-ILD patients were included. Patients with higher RR levels (≥ 1.5 mg/L) had a significantly better FVC evolution with a higher proportion of stabilization and lower proportion of FVC decrease (p = 0.024). RR above 1.5 mg/L was a predictive factor of reduced FVC decline compared with lower RR levels adjusting for MMF dose and duration of MMF exposure (p = 0.008). There was no difference regarding DLCO outcome.
CONCLUSION
CONCLUSIONS
Our study suggests that optimal MPA exposure, as indicated by RR levels, may better protect against FVC decline in SSc-ILD patients treated with MMF. Routine monitoring of MPA exposure could be beneficial in optimizing treatment outcomes. Prospective, multicenter studies are needed to further explore the relationship between MPA exposure and clinical outcomes in SSc-ILD.
Identifiants
pubmed: 39468495
doi: 10.1186/s12890-024-03361-7
pii: 10.1186/s12890-024-03361-7
doi:
Substances chimiques
Mycophenolic Acid
HU9DX48N0T
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
537Informations de copyright
© 2024. The Author(s).
Références
Tamby MC, Chanseaud Y, Guillevin L, Mouthon L. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev. 2003;2(3):152–7.
doi: 10.1016/S1568-9972(03)00004-1
pubmed: 12848956
Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev. 2010;9(5):A311–318.
doi: 10.1016/j.autrev.2009.11.003
pubmed: 19906362
D’Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46(3):428–40.
doi: 10.1016/0002-9343(69)90044-8
pubmed: 5780367
Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev. 2013;22(127):6–19.
doi: 10.1183/09059180.00005512
pubmed: 23457159
pmcid: 4103193
Steen VD, Conte C, Owens GR, Medsger TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37(9):1283–9.
doi: 10.1002/art.1780370903
pubmed: 7945490
Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897–905.
doi: 10.1136/annrheumdis-2017-211448
pubmed: 28835464
Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–39.
doi: 10.1136/annrheumdis-2016-209909
pubmed: 27941129
Hachulla E, Agard C, Allanore Y, Avouac J, Bader-Meunier B, Belot A, et al. French recommendations for the management of systemic sclerosis. Orphanet J Rare Dis. 2021;16(Suppl 2):322.
doi: 10.1186/s13023-021-01844-y
pubmed: 34304732
pmcid: 8310704
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708–19.
doi: 10.1016/S2213-2600(16)30152-7
pubmed: 27469583
pmcid: 5014629
Dong M, Fukuda T, Vinks AA. Optimization of mycophenolic acid therapy using clinical pharmacometrics. Drug Metab Pharmacokinet. 2014;29(1):4–11.
doi: 10.2133/dmpk.DMPK-13-RV-112
pubmed: 24351871
Benjanuwattra J, Pruksakorn D, Koonrungsesomboon N. Mycophenolic Acid and Its Pharmacokinetic Drug-Drug Interactions in Humans: review of the evidence and clinical implications. J Clin Pharmacol. 2020;60(3):295–311.
doi: 10.1002/jcph.1565
pubmed: 31814154
Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219–28.
doi: 10.1056/NEJMoa043731
pubmed: 16306519
Iaccarino L, Rampudda M, Canova M, Della Libera S, Sarzi-Puttinic P, Doria A. Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev. 2007;6(3):190–5.
doi: 10.1016/j.autrev.2006.11.001
pubmed: 17289556
Eskin-Schwartz M, David M, Mimouni D. Mycophenolate mofetil for the management of autoimmune bullous diseases. Dermatol Clin. 2011;29(4):555–9.
doi: 10.1016/j.det.2011.06.012
pubmed: 21924997
Chaigne B, Gatault P, Darrouzain F, Barbet C, Degenne D, François M, et al. Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective pharmacokinetics and clinical study. Clin Exp Immunol. 2014;176(2):172–9.
doi: 10.1111/cei.12246
pubmed: 24304103
pmcid: 3992029
van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28(2):145–54.
doi: 10.1097/01.ftd.0000199358.80013.bd
pubmed: 16628123
Zahr N, Arnaud L, Marquet P, Haroche J, Costedoat-Chalumeau N, Hulot JS, et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum. 2010;62(7):2047–54.
doi: 10.1002/art.27495
pubmed: 20506558
Wakahashi K, Yamamori M, Minagawa K, Ishii S, Nishikawa S, Shimoyama M, et al. Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation. Int J Hematol. 2011;94(2):193–202.
doi: 10.1007/s12185-011-0888-6
pubmed: 21751082
Fernández-Codina A, Walker KM, Pope JE, Scleroderma Algorithm Group. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol. 2018;70(11):1820–8.
doi: 10.1002/art.40560
pubmed: 29781586
Alex G, Shanoj KC, Varghese DR, SageerBabu AS, Reji R, Shenoy PD. Co prescription of anti-acid therapy reduces the bioavailability of mycophenolate mofetil in systemic sclerosis patients: a crossover trial. Semin Arthritis Rheum. 2023;63:152270.
doi: 10.1016/j.semarthrit.2023.152270
pubmed: 37820508
Andréasson K, Neringer K, Wuttge DM, Henrohn D, Marsal J, Hesselstrand R. Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation-a prospective, observational study. Arthritis Res Ther. 2020;22(1):230.
doi: 10.1186/s13075-020-02323-8
pubmed: 33023643
pmcid: 7539387
Legendre P, Blanchet B, Porcher R, Bérezné A, Allard M, London J, et al. Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: a monocentric and retrospective French study. J Scleroderma Relat Disord. 2021;6(1):87–95.
doi: 10.1177/2397198320944342
pubmed: 35382246
Le Meur Y, Büchler M, Thierry A, Caillard S, Villemain F, Lavaud S, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7(11):2496–503.
doi: 10.1111/j.1600-6143.2007.01983.x
pubmed: 17908276
Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, et al. Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2021;43(2):150–200.
doi: 10.1097/FTD.0000000000000871
pubmed: 33711005
Wuttiputhanun T, Naiyarakseree N, Udomkarnjananun S, Kittanamongkolchai W, Asada L, Chariyavilaskul P, et al. Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis. Lupus Sci Med. 2024;11(1):e001093.
doi: 10.1136/lupus-2023-001093
pubmed: 38233072
pmcid: 10806523
van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–55.
doi: 10.1136/annrheumdis-2013-204424
pubmed: 24092682
Wells AU, Margaritopoulos GA, Antoniou KM, Denton C. Interstitial lung disease in systemic sclerosis. Semin Respir Crit Care Med. 2014;35(2):213–21.
doi: 10.1055/s-0034-1371541
pubmed: 24668536
Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–47.
doi: 10.1164/rccm.202202-0399ST
pubmed: 35486072
pmcid: 9851481
Streit F, Shipkova M, Armstrong VW, Oellerich M. Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid. Clin Chem. 2004;50(1):152–9.
doi: 10.1373/clinchem.2003.024323
pubmed: 14633915
Liossis SNC, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006;45(8):1005–8.
doi: 10.1093/rheumatology/kei211
pubmed: 16490756
Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E, et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol. 2007;25(2):287–92.
pubmed: 17543155
Herman D, Ghazipura M, Barnes H, Macrea M, Knight SL, Silver RM, et al. Mycophenolate in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis. Ann Am Thorac Soc. 2024;21(1):136–50.
doi: 10.1513/AnnalsATS.202301-054OC
pubmed: 37027538
Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol. 2012;39(6):1241–7.
doi: 10.3899/jrheum.111229
pubmed: 22467932
Le EN, Wigley FM, Shah AA, Boin F, Hummers LK. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2011;70(6):1104–7.
doi: 10.1136/ard.2010.142000
pubmed: 21378404
Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford). 2009;48(12):1595–9.
doi: 10.1093/rheumatology/kep295
pubmed: 19846575
Streicher C, Djabarouti S, Xuereb F, Lazaro E, Legeron R, Bouchet S, et al. Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases. Br J Clin Pharmacol. 2014;78(6):1419–25.
doi: 10.1111/bcp.12462
pubmed: 25041114
pmcid: 4256630
Schaier M, Scholl C, Scharpf D, Schmitt WH, Schwenger V, Zeier M, et al. High interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitis. Nephrol Dial Transplant. 2015;30(Suppl 1):i138–145.
doi: 10.1093/ndt/gfv065
pubmed: 25805745
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–27.
doi: 10.1056/NEJMoa1908681
pubmed: 31566307